A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (Pegloticase) (MIRROR Open-Label [OL])
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Methotrexate (Primary) ; Pegloticase (Primary)
- Indications Gout
- Focus Therapeutic Use
- Acronyms MIRROR; MIRROR OL
- Sponsors Horizon Pharma Rheumatology; Horizon Therapeutics plc
- 31 May 2019 Phase has been changed from Phase II to Phase IV.
- 31 May 2019 Status changed from recruiting to active, no longer recruiting.
- 31 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.